Safety and Efficacy of Urinary Kallidinogenase for Large Artery Atherosclerosis Acute Ischemic Stroke

Prior treatment

• Patients who planned or had received emergency reperfusion therapy (including intravenous thrombolysis and emergency thrombectomy);
• Patients who previously received angiotensin-converting enzyme inhibitor (ACEI) drugs regularly;
• Participating in other clinical investigators, or had participated in other clinical investigators within 3 months before enrollment;

Other illness

• Refractory hypertension: systolic blood pressure ≥200 mmHg or diastolic blood pressure ≥110 mmHg; hypotension: systolic blood pressure \< 90 mmHg or diastolic blood pressure \< 60 mmHg;
• Cardioembolic stroke or high-risk factors of cardioembolic stroke identified by investigators (atrial fibrillation, cardiac mural thrombus, cardiomyopathy, etc.);
• Other conditions considered by the investigator to be inappropriate for enrollment.

Lab values

• Liver dysfunction (ALT/AST \>1.5 × upper limit of normal \[ULN\]), renal dysfunction (Cr \>1 × ULN);
• Coagulopathy (prolonged INR (\>1.5) or prolonged APTT (\>2 folds);

Other

• Transient ischemic attack;
• Severe disturbance of consciousness:GCS ≤8;
• Special populations such as pregnant and lactating women, patients with life expectancy less than 3 months, or patients unable to complete the study for other reasons;
• Unwilling to be followed up or poor treatment compliance;

• Age ≥18 years old;
• Acute anterior circulation large artery atherosclerotic cerebral infarction (according to TOAST classification) within 48h of onset; NIHSS score ≥6, ≤15;
• Moderate to severe stenosis or occlusion of offending vessels;
• The mRS Score ≤2 before onset;
• Subjects or their legal representatives agreed to the treatment and signed the informed consent form.